雷帕霉素和紫杉醇药物洗脱支架治疗冠状动脉开口病变:1年随访评价有效和安全性  

Rapamycin-eluting stent versus paclitaxel-eluting stent for coronary ostial lesions: effective and safety evaluation after 1-year follow-up

作　　者：陈小龙[1] 

机构地区：[1]南阳医学高等专科学校第一附属医院心血管内科,河南省南阳市473000

出　　处：《中国组织工程研究》2016年第34期5110-5115,共6页Chinese Journal of Tissue Engineering Research

摘　　要：背景:雷帕霉素和紫杉醇药物洗脱支架被广泛应用于冠状动脉开口病变治疗(左主干开口和右冠开口病变),但有关两者治疗有效性和安全性的对比研究较少。目的:对比雷帕霉素和紫杉醇药物洗脱支架置入治疗冠状动脉开口病变的有效性和安全性。方法:纳入135例冠状动脉开口病变患者,按随机数表法将患者分为2组,其中62例在冠状动脉开口处置入紫杉醇洗脱支架,73例在冠状动脉开口处置入雷帕霉素洗脱支架。置入后随访12个月,对比两组心脏不良事件发生率、血栓形成、靶病变血运重建及支架再狭窄情况。结果与结论:(1)两组均未发生支架脱落或移位,未发生与支架材料相关的不良反应;(2)雷帕霉素洗脱支架组与紫杉醇洗脱支架组心脏不良事件发生率(8.5%、6.8%)、血栓形成发生率(3.9%、4.1%)、靶病变血运重建率(4.1%、6.4%)、支架内再狭窄率(7.5%、9.2%)比较差异均无显著性意义;(3)结果表明:雷帕霉素与紫杉醇药物洗脱支架置入治疗冠状动脉开口病变的有效性和安全性相当。BACKGROUND：Rapamycin and paclitaxel eluting stents have been widely used in the treatment of coronary ostial lesions （left main coronary artery and right coronary artery ostial lesions）. However, the comparative researchon the effectiveness and safety of the two stentsfor coronary ostial lesions is relatively rare. OBJECTIVE：To explore the efficacy and safety of the rapamycin-eluting stentversuspaclitaxel-eluting stent in the treatment of coronary ostial lesions. METHODS：135 patients with coronary ostial lesions were selected and were alotted into two groups by random number table, 73 cases treated with rapamycin-eluting stentand the remaining 62 cases treated with paclitaxel-eluting stent.After 12-monthfolow-up, the incidence of adverse cardiac events, thrombosis, target lesion revascularization and stent-restenosis were compared between two groups. RESULTS AND CONCLUSION：Neither didstent dropoff or displace,nor didother adverse reactions related to the stent occurr in both two groups. The incidence of cardiac adverse events in the rapamycin group and paclitaxel group was 8.5% and 6.8%; the rate of thrombosis was 3.9% and 4.1%; the rate of the target lesion revascularization was 4.1% and 6.4%; the rate of stent-restenosis was 7.5% and 9.2%, respectively.Al above indicatorsshowedno significant differences between two groups. In conclusion, the efficacy and safety of the rapamycin-eluting stent for coronary ostial lesionsareequivalent to those of the paclitaxel-eluting stent.

关 键 词：生物材料 材料相容性 雷帕霉素洗脱支架 紫杉醇洗脱支架 冠状动脉开口病变 心血管事件 有效性 安全性 

分 类 号：R318[医药卫生—生物医学工程]